Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of “Moderate Buy” from Analysts
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has received a consensus rating of “Moderate Buy” from the nineteen analysts that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 1-year price target among brokers […]
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has received a consensus rating of “Moderate Buy” from the nineteen analysts that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 1-year price target among brokers […]
